← Back to Clinical Trials
Recruiting NCT07110714

NCT07110714 Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07110714
Status Recruiting
Phase
Sponsor Eggensberger OHG
Condition Post COVID-19 Condition
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-12-01
Primary Completion 2027-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cold water hydrotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9) * Barthel-Index \>80 * Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability * Written informed consent Exclusion Criteria: * Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy) * Prior regular practice of Kneipp applications

Contact & Investigator

Central Contact

Andreas Eggensberger, MSc

✉ a.eggensberger@eggensberger.de

📞 +4983629103300

Principal Investigator

Rembert Koczulla, MD

PRINCIPAL INVESTIGATOR

Schön Klinik Berchtesgadener Land

Frequently Asked Questions

Who can join the NCT07110714 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Post COVID-19 Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07110714 currently recruiting?

Yes, NCT07110714 is actively recruiting participants. Contact the research team at a.eggensberger@eggensberger.de for enrollment information.

Where is the NCT07110714 trial being conducted?

This trial is being conducted at Füssen, Germany.

Who is sponsoring the NCT07110714 clinical trial?

NCT07110714 is sponsored by Eggensberger OHG. The principal investigator is Rembert Koczulla, MD at Schön Klinik Berchtesgadener Land. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology